Cargando…

Dynamic Metabolic Changes during the First 3 Months after (90)Y-Ibritumomab Tiuxetan Radioimmunotherapy

Objective. To elucidate the time course of tumor metabolism during the first 3 months after (90)Y-ibritumomab tiuxetan radioimmunotherapy (RIT) in patients with refractory malignant lymphoma. Materials and Methods. Seven patients with recurrent follicular lymphoma underwent FDG-PET imaging before an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takahashi, Miwako, Momose, Toshimitsu, Koyama, Keitaro, Ichikawa, Motoshi, Kurokawa, Mineo, Ohtomo, Kuni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090517/ https://www.ncbi.nlm.nih.gov/pubmed/25050390 http://dx.doi.org/10.1155/2014/368947

Ejemplares similares

90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity
por: Mondello, Patrizia, et al.
Publicado: (2015)

Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma
por: Lehnert, Martina, et al.
Publicado: (2009)

Biodistribution, radiation dosimetry and scouting of (90)Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using (89)Zr-ibritumomab tiuxetan and PET
por: Rizvi, Saiyada N. F., et al.
Publicado: (2012)

RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution
por: Andrade Campos, Marcio Miguel, et al.
Publicado: (2012)

(90)Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin’s lymphoma: current status and future prospects
por: Jacobs, Samuel A
Publicado: (2007)

Bulky Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan
por: Tamura, Shinobu, et al.
Publicado: (2013)

A new pharmacokinetic model for (90)Y-ibritumomab tiuxetan based on 3-dimensional dosimetry
por: Morschhauser, F., et al.
Publicado: (2018)

The standardized uptake value calculated from (111)In-ibritumomab tiuxetan single-photon emission computed tomography/computed tomography is a useful predictor of the clinical response in patients treated by (90)Y- ibritumomab tiuxetan therapy
por: Kume, Ayaka, et al.
Publicado: (2021)

Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma
por: Hanaoka, Kohei, et al.
Publicado: (2015)

Review of (90)Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin’s lymphoma
por: Emmanouilides, Christos
Publicado: (2009)

Efficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin’s lymphoma
por: Ferrucci, PF, et al.
Publicado: (2008)

Megadose (90)Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma
por: Chow, Victor A., et al.
Publicado: (2021)

Outcomes after (90)Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis
por: Auger-Quittet, Sophie, et al.
Publicado: (2014)

(90)Y-Ibritumomab tiuxetan followed by reduced-intensity conditioning and allogeneic stem-cell transplantation in patients with advanced follicular lymphoma
por: Abou-Nassar, Karim E., et al.
Publicado: (2011)

(90)Y-ibritumomab Tiuxetan in B-cell Non-Hodgkin Lymphomas: Real-world Data From the United Arab Emirates
por: Szakács, Zsolt, et al.
Publicado: (2021)

(90)Yttrium Ibritumomab Tiuxetan (Zevalin) for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Report of 5 Cases
por: Wang, Jing, et al.
Publicado: (2023)

90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years
por: Rieger, Kathrin, et al.
Publicado: (2022)

Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
por: Lane, Michael A., et al.
Publicado: (2015)

Preoperative Evaluation of Renal Cell Carcinoma by Using 18F-FDG PET/CT
por: Takahashi, Miwako, et al.
Publicado: (2015)

The use of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation
por: Jurczak, Wojciech, et al.
Publicado: (2015)

Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma
por: Pisani, Francesco, et al.
Publicado: (2015)

Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma
por: Jo, Jae-Cheol, et al.
Publicado: (2012)

FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by (90)yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases
por: Pisani, Francesco, et al.
Publicado: (2011)

Single-Dose Cisplatin Pre-Treatment Enhances Efficacy of ROBO1-Targeted Radioimmunotherapy
por: Fujiwara, Kentaro, et al.
Publicado: (2020)

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 ((111)In)/Yttrium 90 ((90)Y) Ibritumomab Tiuxetan (Zevalin(®)) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels
por: Wahl, Richard L., et al.
Publicado: (2021)

90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: updated long‐term results after a median follow‐up of 7 years
por: Casadei, Beatrice, et al.
Publicado: (2016)

Efficacy and Limitations of rCBF-SPECT in the Diagnosis of Alzheimer’s Disease With Amyloid-PET
por: Takahashi, Miwako, et al.
Publicado: (2019)

Two Cases of Decreased (123)I-Metaiodobenzylguanidine Lung Uptake in Metaiodobenzylguanidine Scintigraphy While Taking Selective Serotonin Reuptake Inhibitor/Serotonin Noradrenaline Reuptake Inhibitor
por: Adaniya, Shinobu, et al.
Publicado: (2021)

Influence of antidepressant use on (123)I-MIBG heart and lung uptakes in the diagnosis of Lewy body disease
por: Adaniya, Shinobu, et al.
Publicado: (2022)

Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results
por: Stefoni, V, et al.
Publicado: (2016)

A (90)Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy
por: Fujiwara, Kentaro, et al.
Publicado: (2014)

An automated voxel-based method for calculating the reference value for a brain tumour metabolic index using (18)F-FDG-PET and (11)C-methionine PET
por: Takahashi, Miwako, et al.
Publicado: (2017)

Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma
por: Tardy, Magalie P., et al.
Publicado: (2015)

Resistance to ibritumomab in lymphoma
por: Kumar, Lalit
Publicado: (2020)

Combined treatment of pancreatic cancer xenograft with (90)Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor
por: Aung, Winn, et al.
Publicado: (2017)

A case of recurrent depressive disorder presenting with Alice in Wonderland syndrome: psychopathology and pre- and post-treatment FDG-PET findings
por: Yokoyama, Tatsushi, et al.
Publicado: (2017)

Case Report: Guanfacine and methylphenidate improved chronic lower back pain in autosomal dominant polycystic kidney disease with comorbid attention deficit hyperactivity disorder and autism spectrum disorder
por: Kasahara, Satoshi, et al.
Publicado: (2023)

Ansa pancreatica as a predisposing factor for recurrent acute pancreatitis
por: Hayashi, Takana Yamakawa, et al.
Publicado: (2016)

Percutaneous transluminal renal angioplasty with stenting for stenotic venous bypass grafts: report of two cases
por: Kusakabe, Masashi, et al.
Publicado: (2013)

Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study
por: Grana, C, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_3d3afnae74k29vq5rsb205bkig